Search reports.
COVID 19 Vaccines Production Capacity & Development Timeline Market
Get free sample report Request for Customiztion Buy Now

COVID 19 Vaccines Production Capacity & Development Timeline Market

Segments - COVID-19 Vaccines-Production Capacity & Development Timeline Market by Types (Virus-like Particle, Whole Virus, Protein, Antibodies, Viral Vector, and mRNA/DNA), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

https://growthmarketreports.com/raksha
Author : Raksha Sharma
https://growthmarketreports.com/Vaibhav
Fact-checked by : V. Chandola
https://growthmarketreports.com/Vishal
Editor : Vishal Golekar

Upcoming | Report ID :HC-1999 | 4.3 Rating | 63 Reviews | 192 Pages | Format : PDF Excel PPT

Report Description


The global COVID-19 vaccines-production capacity & development timeline market size is projected to expand at a substantial CAGR during the forecast period, 2021–2028. In early months of 2021, many companies had entered phase II trials of several vaccines across the globe and were ready to launch them for the public use. Rising investment from various research groups and their unparalleled research efforts with respect to scale and speed up the development of drugs are projected to expand the market. The COVID-19 vaccine development is growing faster than other vaccines development as other vaccines needed general time slot about 20 years. For instance, the development of Human Papilloma Virus (HPV) vaccine took about 26 years while the development of the Respiratory Syncytial Virus (RSV) vaccine took more than 50 years.

Global COVID 19 Vaccines Production Capacity & Development Timeline Market Key Takeaways

World Health Organization (WHO) and the government regulatory bodies had taken various initiatives for early research and vaccine development. The Coalition for Epidemic Preparedness Innovations (CEPI) and WHO have conducted the COVAX vaccine initiative for rapid development and rising access to contributing economy. These bodies also jointly working for enhancement of manufacturing capacity and proficient management of the buyer-supplier chain, to enable correct distribution of more than 2 billion doses by the end of 2021. Till August 2020, around 170 countries were present for the discussion of potential participation in COVAX.

As COVID-19 vaccine is considered to be a non-profit making market, therefore funding from governments is a major concern. Biomedical Advanced Research and Development Authority (BARDA) guided small companies for their benefits. BARDA helps in simplification of communication between regulatory agencies and provides guidance for trial design and expectations of regulatory agencies. Sanofi entered into a partnership with BARDA and GSK for its traditional vaccine, which was based on the further development of baculovirus expression system. Based on manufacturer’s and payer’s perspective, the Quality Adjusted Life Year (QALY) and Case Fatality Ratio (CFR) are also considered and vaccine pricing is set differently than other drugs pricing. The pricing depends on incidence of COVID-19, which motivate immunologists for rising focus on infection and development of exciting platforms.

  • Increasing vaccine product supply to meet the enormous demand across the globe is one of the major factor responsible for driving the market growth.
  • Rising government funding, increasing company investments, and quicker regulatory approvals are expected to fuel the market growth during the forecast period.
  • Growing initiatives from regulatory bodies, arrival of next-generation vaccine platforms, and growing number of COVID-19 patients are anticipated to boost the market expansion in coming years.
  • High cost operation related with R&D activities and long timeline for the development of therapeutic drugs and vaccines, required complex steps for the approval of every phase of clinical trials are estimated to impede the growth of the market.
  • Stringent regulation and high cost associated with per dose vaccine are major factors to restrict the market growth during the forecast period.

Scope of the Report

The report on the global COVID-19 vaccines-production capacity & development timeline market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

COVID-19 Vaccines-Production Capacity & Development Timeline Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Types (Virus-like Particle, Whole Virus, Protein, Antibodies, Viral Vector, and mRNA/DNA)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Pfizer, Moderna, BioNtech, Sanofi, Zydus Cadila, CureVac, Imperial College London, Takara Bio, CanSino Biologics, Beth Israel Deaconess Medical Center, ReiThera, Novartis, Anhui Zhifei Longcom, Novavax, and the University of Queensland.

Market Segment Insights

Protein segment is projected to hold a major market share

Based on types, the COVID-19 vaccines-production capacity & development timeline market is segmented into virus-like particle (VLP), whole virus, protein, antibodies, viral vector, and mRNA/DNA. The protein segment is expected to hold a key share of the market during the forecast period. This type of vaccine consists of purified pieces of pathogen to trigger the immune response. Owing to appearance of significant positive effects, the adoption of these vaccines are constantly increasing during the recent months.

On the other hand, the viral vector segment is anticipated to expand at a rapid pace during the forecast period owing to presence of manufacturing infrastructure that helps the development of effective vaccine in lesser time period. The whole virus type vaccine is used as deactivated and weakened pathogens, which triggers protective immunity. Inactivated pathogens are used by Sinopharm and Sinovac. The VLP vaccines consist of inactivated and weakened viruses. The protein-based vaccines are dominating the market for clinical trials. Many researchers and developers are focusing on evaluating and monitoring spike (S) protein.

Global COVID 19 Vaccines Production Capacity & Development Timeline Market Types

North America is expected to dominate the market

On the basis of regions, the COVID-19 vaccines-production capacity & development timeline market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to dominate the market during the forecast period owing to presence of multiple private organizations and academic institutes for developing vaccines. In the U.S., the Operation Warp Speed (OWS) is a key national program for various strategies related to vaccine development, therapeutics, and detection of coronavirus.

Global COVID 19 Vaccines Production Capacity & Development Timeline Market Region

Segments

Segments Covered in the Report
The global COVID-19 vaccines-production capacity & development timeline market has been segmented on the basis of
Types

  • Virus-like Particle
  • Whole Virus
  • Protein
  • Antibodies
  • Viral Vector
  • mRNA/DNA

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • Pfizer
  • Moderna
  • BioNtech
  • Sanofi
  • Zydus Cadila
  • CureVac
  • Imperial College London
  • Takara Bio
  • CanSino Biologics
  • Beth Israel Deaconess Medical Center
  • ReiThera
  • Novartis
  • Anhui Zhifei Longcom
  • Novavax
  • University of Queensland

 

Competitive Landscape

Key players competing in the COVID-19 vaccines-production capacity & development timeline market include Pfizer, Moderna, BioNtech, Sanofi, Zydus Cadila, CureVac, Imperial College London, Takara Bio, CanSino Biologics, Beth Israel Deaconess Medical Center, ReiThera, Novartis, Anhui Zhifei Longcom, Novavax, and the University of Queensland.

Many of these market players are looking at opportunities to implement business strategies such as mergers, acquisitions, partnerships, capacity expansion, and product launches to enhance their market shares. Companies are also adopting collaboration strategy for the best result and early launch of vaccines. For instance, Moderna collaborated with Lonza, AstraZeneca with Serum Institute of India and Pfizer, and BioNTech with Pfizer to expand their product portfolio.

Global COVID 19 Vaccines Production Capacity & Development Timeline Market Key Players

Table Of Content

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. COVID-19 Vaccines-Production Capacity & Development Timeline Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. COVID-19 Vaccines-Production Capacity & Development Timeline Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. COVID-19 Vaccines-Production Capacity & Development Timeline Market - Supply Chain
  4.5. Global COVID-19 Vaccines-Production Capacity & Development Timeline Market Forecast
     4.5.1. COVID-19 Vaccines-Production Capacity & Development Timeline Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. COVID-19 Vaccines-Production Capacity & Development Timeline Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. COVID-19 Vaccines-Production Capacity & Development Timeline Market Absolute $ Opportunity
5. Global COVID-19 Vaccines-Production Capacity & Development Timeline Market Analysis and Forecast by Types
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Types
     5.2.2. Y-o-Y Growth Projections by Types
  5.3. COVID-19 Vaccines-Production Capacity & Development Timeline Market Size and Volume Forecast by Types
     5.3.1. Virus-like Particle
     5.3.2. Whole Virus
     5.3.3. Protein
     5.3.4. Antibodies
     5.3.5. Viral Vector
     5.3.6. mRNA/DNA
  5.4. Absolute $ Opportunity Assessment by Types
  5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global COVID-19 Vaccines-Production Capacity & Development Timeline Market Analysis and Forecast by Region
  6.1. Market Trends
  6.2. Introduction
     6.2.1. Basis Point Share (BPS) Analysis by Region
     6.2.2. Y-o-Y Growth Projections by Region
  6.3. COVID-19 Vaccines-Production Capacity & Development Timeline Market Size and Volume Forecast by Region
     6.3.1. North America
     6.3.2. Latin America
     6.3.3. Europe
     6.3.4. Asia Pacific
     6.3.5. Middle East and Africa (MEA)
  6.4. Absolute $ Opportunity Assessment by Region
  6.5. Market Attractiveness/Growth Potential Analysis by Region
  6.6. Global COVID-19 Vaccines-Production Capacity & Development Timeline Demand Share Forecast, 2019-2026
7. North America COVID-19 Vaccines-Production Capacity & Development Timeline Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
  7.2. North America COVID-19 Vaccines-Production Capacity & Development Timeline Market Size and Volume Forecast by Country
     7.2.1. U.S.
     7.2.2. Canada
  7.3. Absolute $ Opportunity Assessment by Country
  7.4. North America COVID-19 Vaccines-Production Capacity & Development Timeline Market Size and Volume Forecast by Types
     7.4.1. Virus-like Particle
     7.4.2. Whole Virus
     7.4.3. Protein
     7.4.4. Antibodies
     7.4.5. Viral Vector
     7.4.6. mRNA/DNA
  7.5. Basis Point Share (BPS) Analysis by Types
  7.6. Y-o-Y Growth Projections by Types
  7.7. Market Attractiveness/Growth Potential Analysis
     7.7.1. By Country
     7.7.2. By Product Type
     7.7.3. By Application
  7.8. North America COVID-19 Vaccines-Production Capacity & Development Timeline Demand Share Forecast, 2019-2026
8. Latin America COVID-19 Vaccines-Production Capacity & Development Timeline Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Latin America Average Pricing Analysis
  8.2. Latin America COVID-19 Vaccines-Production Capacity & Development Timeline Market Size and Volume Forecast by Country
      8.2.1. Brazil
      8.2.2. Mexico
      8.2.3. Rest of Latin America
   8.3. Absolute $ Opportunity Assessment by Country
  8.4. Latin America COVID-19 Vaccines-Production Capacity & Development Timeline Market Size and Volume Forecast by Types
     8.4.1. Virus-like Particle
     8.4.2. Whole Virus
     8.4.3. Protein
     8.4.4. Antibodies
     8.4.5. Viral Vector
     8.4.6. mRNA/DNA
  8.5. Basis Point Share (BPS) Analysis by Types
  8.6. Y-o-Y Growth Projections by Types
  8.7. Market Attractiveness/Growth Potential Analysis
     8.7.1. By Country
     8.7.2. By Product Type
     8.7.3. By Application
  8.8. Latin America COVID-19 Vaccines-Production Capacity & Development Timeline Demand Share Forecast, 2019-2026
9. Europe COVID-19 Vaccines-Production Capacity & Development Timeline Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Europe Average Pricing Analysis
  9.2. Europe COVID-19 Vaccines-Production Capacity & Development Timeline Market Size and Volume Forecast by Country
     9.2.1. Germany
     9.2.2. France
     9.2.3. Italy
     9.2.4. U.K.
     9.2.5. Spain
     9.2.6. Russia
     9.2.7. Rest of Europe
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Europe COVID-19 Vaccines-Production Capacity & Development Timeline Market Size and Volume Forecast by Types
     9.4.1. Virus-like Particle
     9.4.2. Whole Virus
     9.4.3. Protein
     9.4.4. Antibodies
     9.4.5. Viral Vector
     9.4.6. mRNA/DNA
  9.5. Basis Point Share (BPS) Analysis by Types
  9.6. Y-o-Y Growth Projections by Types
  9.7. Market Attractiveness/Growth Potential Analysis
     9.7.1. By Country
     9.7.2. By Product Type
     9.7.3. By Application
  9.8. Europe COVID-19 Vaccines-Production Capacity & Development Timeline Demand Share Forecast, 2019-2026
10. Asia Pacific COVID-19 Vaccines-Production Capacity & Development Timeline Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Asia Pacific Average Pricing Analysis
  10.2. Asia Pacific COVID-19 Vaccines-Production Capacity & Development Timeline Market Size and Volume Forecast by Country
     10.2.1. China
     10.2.2. Japan
     10.2.3. South Korea
     10.2.4. India
     10.2.5. Australia
     10.2.6. Rest of Asia Pacific (APAC)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Asia Pacific COVID-19 Vaccines-Production Capacity & Development Timeline Market Size and Volume Forecast by Types
     10.4.1. Virus-like Particle
     10.4.2. Whole Virus
     10.4.3. Protein
     10.4.4. Antibodies
     10.4.5. Viral Vector
     10.4.6. mRNA/DNA
  10.5. Basis Point Share (BPS) Analysis by Types
  10.6. Y-o-Y Growth Projections by Types
  10.7. Market Attractiveness/Growth Potential Analysis
     10.7.1. By Country
     10.7.2. By Product Type
     10.7.3. By Application
  10.8. Asia Pacific COVID-19 Vaccines-Production Capacity & Development Timeline Demand Share Forecast, 2019-2026
11. Middle East & Africa COVID-19 Vaccines-Production Capacity & Development Timeline Market Analysis and Forecast
  11.1. Introduction
     11.1.1. Basis Point Share (BPS) Analysis by Country
     11.1.2. Y-o-Y Growth Projections by Country
     11.1.3. Middle East & Africa Average Pricing Analysis
  11.2. Middle East & Africa COVID-19 Vaccines-Production Capacity & Development Timeline Market Size and Volume Forecast by Country
     11.2.1. Saudi Arabia
     11.2.2. South Africa
     11.2.3. UAE
     11.2.4. Rest of Middle East & Africa (MEA)
  11.3. Absolute $ Opportunity Assessment by Country
  11.4. Middle East & Africa COVID-19 Vaccines-Production Capacity & Development Timeline Market Size and Volume Forecast by Types
     11.4.1. Virus-like Particle
     11.4.2. Whole Virus
     11.4.3. Protein
     11.4.4. Antibodies
     11.4.5. Viral Vector
     11.4.6. mRNA/DNA
  11.5. Basis Point Share (BPS) Analysis by Types
  11.6. Y-o-Y Growth Projections by Types
  11.7. Market Attractiveness/Growth Potential Analysis
     11.7.1. By Country
     11.7.2. By Product Type
     11.7.3. By Application
  11.8. Middle East & Africa COVID-19 Vaccines-Production Capacity & Development Timeline Demand Share Forecast, 2019-2026
12. Competition Landscape
  12.1. Global COVID-19 Vaccines-Production Capacity & Development Timeline Market: Market Share Analysis
  12.2. COVID-19 Vaccines-Production Capacity & Development Timeline Distributors and Customers
  12.3. COVID-19 Vaccines-Production Capacity & Development Timeline Market: Competitive Dashboard
  12.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     12.4.1. Pfizer
     12.4.2. Moderna
     12.4.3. BioNtech
     12.4.4. Sanofi
     12.4.5. Zydus Cadila
     12.4.6. CureVac
     12.4.7. Imperial College London
     12.4.8. Takara Bio

Methodology

Our Clients

Microsoft
The John Holland Group
FedEx Logistics
General Electric
Siemens Healthcare
Pfizer
Honda Motor Co. Ltd.
Nestle SA